Clinical relevance of genetic polymorphisms in the human CYP2C9 gene (Q35594567)

9 August 2017

1 reference

title

Clinical relevance of genetic polymorphisms in the human CYP2C9 gene (English)

1 reference

9 August 2017

Schwarz UI

1

1 reference

9 August 2017

language of work or name

1 reference

1 November 2003

1 reference

European Journal of Clinical Investigation

9 August 2017

published in

1 reference

9 August 2017

volume

33 Suppl 2

1 reference

9 August 2017

page(s)

23-30

1 reference

Pharmacogenomics: translating functional genomics into rational therapeutics

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Targeted antipeptide antibodies to cytochrome P450 2C18 based on epitope mapping of an inhibitory monoclonal antibody to P450 2C51

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Pharmacogenetics of oral anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Interindividual variability in sensitivity to warfarin--Nature or nurture?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Genetic polymorphisms and functional characterization of the 5'-flanking region of the human CYP2C9 gene: in vitro and in vivo studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Cytochrome P4502C9: an enzyme of major importance in human drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Human P450 metabolism of warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Early acenocoumarol overanticoagulation among cytochrome P450 2C9 poor metabolizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Altered pharmacokinetics of R- and S-acenocoumarol in a subject heterozygous for CYP2C9*3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Tolbutamide, flurbiprofen, and losartan as probes of CYP2C9 activity in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Evaluation of cytochrome P4502C9 metabolic activity with tolbutamide in CYP2C91 heterozygotes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Phenytoin: pharmacogenetic polymorphism of 4'-hydroxylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

The effect of genetic polymorphism of cytochrome P450 CYP2C9 on phenytoin dose requirement

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Enantiospecific effects of cytochrome P450 2C9 amino acid variants on ibuprofen pharmacokinetics and on the inhibition of cyclooxygenases 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

The CYP2C9 genotype predicts the blood pressure response to irbesartan: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA) trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Frequency of cytochrome P450 2C9 mutant alleles in a Korean population

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

The CYP2 family: models, mutants and interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Torsemide metabolism by CYP2C9 variants and other human CYP2C subfamily enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Genetic polymorphism of the CYP2C subfamily and excessive serum phenytoin concentration with central nervous system intoxication

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Structural flexibility and functional versatility of cytochrome P450 and rapid evolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

The warfarin-sulfinpyrazone interaction: stereochemical considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

The possession of the CYP2C9*3 allele is associated with low dose requirement of acenocoumarol

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2362.33.S2.6.X

10.1046/J.1365-2362.33.S2.6.X

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference